Gilead’s cell therapy business Kite cuts 7% of workforce

Gilead’s cell ther­a­py sub­sidiary Kite Phar­ma is let­ting go of rough­ly 300 em­ploy­ees, or about 7% of the unit’s staff.

“We are tak­ing mea­sures to fur­ther align our busi­ness for fu­ture growth, in­clud­ing stream­lin­ing some ar­eas of the or­ga­ni­za­tion to bet­ter op­ti­mize op­er­a­tional ef­fi­cien­cy,” a Gilead spokesper­son con­firmed in an emailed state­ment to End­points News.

In ad­di­tion to the cuts, it’s adding about 90 new jobs to the 4,000-plus-per­son group, mean­ing the net head­count re­duc­tion will be about 5%. Gilead did not re­spond to ques­tions on what as­pects of the cell ther­a­py busi­ness were pri­mar­i­ly im­pact­ed by the lay­offs.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.